Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
- PMID: 25677586
- PMCID: PMC4336503
- DOI: 10.1186/s13075-014-0501-5
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Abstract
Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.
References
-
- Mota LM, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB, Freitas MV, Silva NA, Louzada-Junior P, Giorgi RD, Lima RA, Bernardo WM, Pinheiro Gda R, Sociedade Brasileira de Reumatologia Guidelines for the drug treatment of rheumatoid arthritis. Rev Bras Reumatol. 2013;53:158–183. doi: 10.1590/S0482-50042013000200004. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
